Contingency Medical Countermeasures for Mass Nerve-Agent Exposure: Use of Pharmaceutical Alternatives to Community Stockpiled Antidotes

This work is intended to serve as a resource of pharmaceutical options that may be available to communities when faced with a mass human exposure to a nerve agent and inadequate supplies of medical countermeasures.

HHS, Genentech join forces on medicines to combat influenza, other health security threats

The US Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) announced a strategic partnership with Genentech. The company and ASPR’s Biomedical Advanced Research and Development Authority (BARDA) will focus first on developing a first-in-class therapeutic for hospitalized influenza patients and a treatment for lung injuries caused by inhaling sulfur mustard gas.